Paper Details

  1. Home
  2. Paper Details

Escalating and de-escalating treatment in HER2-positive early breast cancer.

Author: JoensuuHeikki

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review examines current and emerging therapies for early HER2-positive breast cancer. While 12 months of adjuvant trastuzumab remains the standard, clinical trials are investigating shorter durations, dual HER2 inhibition, and longer treatment courses. Results from these trials are expected to inform future treatment guidelines.
Paper Details　
Original Abstract of the Article :
The current standard adjuvant systemic treatment of early HER2-positive breast cancer consists of chemotherapy plus 12months of trastuzumab, with or without endocrine therapy. Several trials have investigated modifications of the standard treatment that are shorter and less resource-demanding (de-es...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ctrv.2016.11.002

データ提供：米国国立医学図書館（NLM）

HER2-Positive Breast Cancer: Tailoring Treatments for a Personalized Approach

This research explores the evolving landscape of [HER2-positive breast cancer] treatment, focusing on the use of [trastuzumab] and other [HER2-targeted therapies]. The study examines the potential of [treatment escalation] and [de-escalation] strategies to optimize patient outcomes and minimize treatment burdens.

HER2-Positive Breast Cancer: Finding the Right Balance Between Treatment Intensity and Effectiveness

The research highlights the potential benefits of [shorter durations] of [trastuzumab] treatment in [HER2-positive breast cancer] patients, potentially minimizing [treatment-related side effects] without compromising [efficacy]. The study also explores the potential of [dual HER2 inhibition] strategies, combining [trastuzumab] with other [HER2-targeted agents] like [lapatinib], [neratinib], or [pertuzumab]. However, further research is needed to determine the optimal [treatment regimen] for each individual patient.

Navigating the Desert of Cancer Treatment: Finding the Right Path for Each Patient

Imagine a camel traversing a vast desert, encountering diverse terrains and challenges. Just as the camel adapts its strategy to each obstacle, doctors must tailor treatment plans to meet the unique needs of each [HER2-positive breast cancer] patient. This research emphasizes the importance of personalized medicine, utilizing [treatment escalation] and [de-escalation] strategies to find the optimal balance between [efficacy] and [minimizing treatment burden].

Dr. Camel's Conclusion

The landscape of [HER2-positive breast cancer] treatment is constantly evolving. Just as a camel adapts its journey to the changing terrain, researchers are working to find the most effective and personalized treatment strategies. This research highlights the potential of [treatment escalation] and [de-escalation] approaches, offering hope for improved patient outcomes and a better quality of life for those battling this disease.
Date :
  1. Date Completed 2017-01-09
  2. Date Revised 2017-01-10
Further Info :

Pubmed ID

27866067

DOI: Digital Object Identifier

10.1016/j.ctrv.2016.11.002

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.